8 enrolling by invitation. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Enrolling by invitation 8 |
| Phase 1 | 2 | Enrolling by invitation 2 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC Bronchial Arterial Chemoembolization (BACE), Systemic anti-tumor combination medications - Non-small Cell Lung Cancer(NSCLC) | Phase 2 | Enrolling by invitation | Fujian Cancer Hospital | 20 | 2026-04-09 | 2026-07-31 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer Adebrelimab + Apatinib - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 2 | Enrolling by invitation | Second Affiliated Hospital of Nanchang University | 37 | 2024-11-01 | 2025-01-14 |
| Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) Durvalumab, Olaparib - Small Cell Lung Carcinoma | Phase 2 | Enrolling by invitation | University of Cologne | 29 | 2024-10-09 | 2025-05-20 |
| Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases Trastuzumab deruxtecan - Non Small Cell Lung Cancer | Phase 2 | Enrolling by invitation | Yonsei University | 27 | 2024-07-11 | 2026-02-09 |
| the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib Trilaciclib - Non-small Cell Lung Cancer | Phase 2 | Enrolling by invitation | Henan Cancer Hospital | 41 | 2024-04-02 | 2026-01-28 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
| Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC split-course adaptive hypofractionated radiotherapy - Small-cell Lung Cancer | Phase 2 | Enrolling by invitation | Fujian Medical University Union Hospital | 35 | 2023-12-26 | 2025-02-10 |
Carcinoma, Non-Small-Cell Lung (5) · Small Cell Lung Carcinoma (3) · Esophageal Neoplasms (2) · Breast Neoplasms (1) · Glioblastoma (1) · Mesothelioma, Malignant (1) · Neurofibrosarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Bronchial Neoplasms (8) · Carcinoma, Bronchogenic (8) · Lung Diseases (8) · Lung Neoplasms (8) · Neoplasms (8) · Neoplasms by Site (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Head and Neck Neoplasms (2)
apatinib (1) · durvalumab (1) · olaparib (1) · trastuzumab deruxtecan (1) · trilaciclib (1)
Fujian Cancer Hospital (1) · Fujian Medical University Union Hospital (1) · Henan Cancer Hospital (1) · Man Hu (1) · Second Affiliated Hospital of Nanchang University (1) · Stella Pharma Corporation (1) · University of Cologne (1) · Yonsei University (1)
China (5) · Germany (1) · Japan (1) · South Korea (1)
Dong Lin Dong Lin, Bachelor of Medicine（BM） (1) · Hye Ryun Kim (1) · Jinghui Lin Jinghui Lin, Bachelor of Medicine(BM) (1) · Lihong Weng Lihong Weng, Master of Medicine (MM) (1) · Man Hu, Dr. (1) · Meifang Li Meifang Li, Bachelor of Medicine（BM） (1) · Qiang Wang Qiang Wang, Bachelor of Medicine(BM) (1) · Shiguang Chen Shiguang Chen, Doctor of Medicine (MD) (1) · Zhiyong He Zhiyong He, Master of Medicine (MM) (1) · Zhuting Fang Zhuting Fang, Doctor of Medicine (MD) (1)
PMID 10561263, PMID 25230595, PMID 30280641, PMID 30285222, PMID 32603550, PMID 33446664, PMID 36907793, PMID 37124525, PMID 38291578, PMID 38655260, PMID 38713298, PMID 38933450, PMID 39177967, PMID 39260670, PMID 40081220, PMID 40140911, PMID 40235787, PMID 40308513, PMID 40969256